| Project/Area Number |
14571249
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Single-year Grants |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | University of Occupational and Environmental Health |
|---|
Principal Investigator |
ITOH Hideaki University of Occupational and Environmental Health, Professor, 医学部, 教授 (90038852)
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
NAKAYAMA Yoshifumi University of Occupational and Environmental Health, Research Associate, 医学部, 助手 (50279337)
NAGATA Naoki University of Occupational and Environmental Health, Assistant Professor, 医学部, 助教授 (80200377)
|
|---|
| Project Period (FY) |
2002 – 2003
|
| Project Status |
Completed (Fiscal Year 2003)
|
| Budget Amount *help |
¥2,700,000 (Direct Cost: ¥2,700,000)
Fiscal Year 2003: ¥1,300,000 (Direct Cost: ¥1,300,000)
Fiscal Year 2002: ¥1,400,000 (Direct Cost: ¥1,400,000)
|
|---|
| Keywords | colorectal carcinoma / hepatic metastasis / retinoid / TAC-101 / angiogenesis / apoptosis / VEGF / Fas / 肝転移抑制 / アポトーシス / 腫瘍血管新生 / 血管新生阻害剤 / vascular endothelial growth factor (VEGF) |
|---|
| Research Abstract |
The presence of hepatic metastasis is one of the most important prognostic factors in colorectal cancer. This suggests that more effective suppressor of the progression and metastasis of colon cancer would significantly improve prognosis. Recently, RA (retinoic acid) has shown to be a potentially powerful anti-cancer agent, and acts in several types of cancer therapy. The mechanism of RA's affect on tumors appears to be related to its effects on proliferation and differentiation of tumor cells. 4-[3,5-bis (trimethylsilyl) benzamido] benzoic acid (TAC-101) is a novel retinobenzoic acid derivative and has a specific binding affinity to the retinoic acid receptors (RAR)-α and -β. TAC-101 has potent anti-proliferative, anti-angiogenic, and anti-tumor effects in vitro and in vivo. However, little is known about the detailed mechanism of TAC-101 function.
Here, we investigate the mechanism of the anti-angiogenic effect and apoptosis induction of TAC-101. Hepatic metastases were induced by por
… More
tal injection of RCN-9 rat colonic cancer cells into F344 rats. TAC-101 was orally administered 5 days per week for four weeks, then liver tumors were immunohistochemically evaluated for microvascular density (MVD) and vascular endothelial growth factor (VEGF). Apoptotic index (A.I.) in the hepatic tumors was evaluated using immunohistochemistry for single-stranded DNA. The proliferative index (P.I.), Fas and Fas ligand were also immunohistochemically evaluated. Moreover, evaluation of apoptosis by TAC-101 in vitro using FACScan analysis was performed in the DLD-1 human colon cancer cell line.
TAC-101 significantly reduced both MVD and VEGF expression. Northern blot analysis and ELISA indicated that TAC-101 efficiently inhibited production of VEGF mRNA and protein in DLD-1 cells in a time-and dose-dependent manner. TAC-101 significantly decreased P. I. but increased A. I. in the hepatic metastatic tumors. TAC-101 did not affect the expression of Fas ligand, but obviously increased the expression of Fas in the metastatic tumors. Moreover, TAC-101 induced early apoptosis in DLD-1 cells in a time dependent manner in vitro.
These findings suggest that TAC-101 may inhibit progression and metastasis in colon cancer by interfering with tumor production of VEGF. Moreover, TAC-101 may induced apoptosis partially through enhanced Fas expression. Less
|
